Acumen Pharmaceuticals (ABOS) Total Current Liabilities (2021 - 2026)

Acumen Pharmaceuticals' Total Current Liabilities history runs 6 years deep, the most recent figure standing at $29.2 million for Q1 2026.

• In Q1 2026, Total Current Liabilities rose 51.33% year-over-year to $29.2 million; the TTM figure through Mar 2026 stood at $29.2 million (up 51.33% YoY), while the FY2025 annual figure was $30.0 million, up 8.69% from the prior year.
• Total Current Liabilities came in at $29.2 million for Q1 2026 at Acumen Pharmaceuticals, down from $30.0 million in the prior quarter.
• In the past five years, Total Current Liabilities ranged from a high of $30.0 million in Q4 2025 to a low of $3.9 million in Q1 2022.
• A 5-year average of $15.1 million and a median of $13.0 million in 2023 frame the typical range for Total Current Liabilities.
• Across the five-year window, Total Current Liabilities decreased 7.79% in 2023 and surged 226.57% in 2024, its largest moves.
• Acumen Pharmaceuticals' Total Current Liabilities stood at $7.8 million in 2022, then surged by 66.04% to $13.0 million in 2023, then jumped by 112.84% to $27.6 million in 2024, then rose by 8.69% to $30.0 million in 2025, then dropped by 2.59% to $29.2 million in 2026.
• According to Business Quant data, Total Current Liabilities over the past three periods registered $29.2 million, $30.0 million, and $22.0 million for Q1 2026, Q4 2025, and Q3 2025 respectively.

Peer Comparison